Given this synergistic effect, we decided to investigate how a breast cancer cell line and a non-cancer cell line responded to a combination of the four potent anti-microtubular drugs together with inhibitors of the mitotic kinases—Plk1, Aurora kinase and cyclin-dependent kinases (CDKs). The gene discussed is PLK1; the disease is breast cancer.